title: Younger adults with acute myeloid leukemia in remission for ≥ 3 years have a high likelihood of cure: The ECOG experience in over 1200 patients.
abstract: We examined 1229 younger patients with acute myeloid leukemia who achieved CR1 on Eastern Cooperative Oncology Group trials. We defined late relapse as occurring after ≥ 3 years of CR1. With median follow-up of 11.3 years, there were 14 late relapses (1.1% of CR1 patients; 3.3% of 3-year CR1 patients). Eight achieved second CR and median overall survival after late relapse was 3.2 years. Most patients tested (9/11) had a normal karyotype at diagnosis; none had new cytogenetic abnormalities at relapse. Late relapse is rare and nearly all 3-year CR1 patients are cured. If late relapse occurs, outcomes are relatively favorable.
authors.affiliation: Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States. Electronic address: wattsj@mskcc.org.
authors.forename: Justin M
authors.initials: JM
authors.lastname: Watts
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, United States; Harvard School of Public Health, Boston, MA, United States.
authors.forename: Xin Victoria
authors.initials: XV
authors.lastname: Wang
authors.affiliation: Mayo Clinic, Rochester, MN, United States.
authors.forename: Mark R
authors.initials: MR
authors.lastname: Litzow
authors.affiliation: University of Pennsylvania, Philadelphia, PA, United States.
authors.forename: Selina M
authors.initials: SM
authors.lastname: Luger
authors.affiliation: Case Western Reserve University, Cleveland, OH, United States.
authors.forename: Hillard M
authors.initials: HM
authors.lastname: Lazarus
authors.affiliation: University of Miami, Miami, FL, United States.
authors.forename: Peter A
authors.initials: PA
authors.lastname: Cassileth
authors.affiliation: H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, United States.
authors.forename: Hugo F
authors.initials: HF
authors.lastname: Fernandez
authors.affiliation: Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
authors.forename: Dan
authors.initials: D
authors.lastname: Douer
authors.affiliation: Dana-Farber Cancer Institute, Boston, MA, United States.
authors.forename: Lynette
authors.initials: L
authors.lastname: Zickl
authors.affiliation: Montefiore Medical Center, Albert Einstein College of Medicine, Bronx, NY, United States.
authors.forename: Elisabeth
authors.initials: E
authors.lastname: Paietta
authors.affiliation: Shaare Zedek Medical Center, Jerusalem, Israel.
authors.forename: Jacob M
authors.initials: JM
authors.lastname: Rowe
authors.affiliation: Leukemia Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
authors.forename: Martin S
authors.initials: MS
authors.lastname: Tallman
mesh_terms: D000328:Adult; D002869:Chromosome Aberrations / Q000706:statistics & numerical data; D018572:Disease-Free Survival; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000453:epidemiology / Q000235:genetics / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D012008:Recurrence; D012074:Remission Induction; D016019:Survival Analysis; D016896:Treatment Outcome; D055815:Young Adult
keywords: Acute myeloid leukemia; Clinical trials; Late relapse; Normal cytogenetics; Outcomes